Narayana Hrudayalaya has uploaded the audio recording of its earnings call for the quarter ended June 30, 2026, providing stakeholders with access to management’s discussion on the company’s financial performance and operational updates. The call was held on August 03, 2026, and addressed investor queries related to the Q1FY27 results.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing follows earlier communications dated July 28, 2026, and July 31, 2026, notifying exchanges of the scheduled event. The audio recording is now available on the company’s website under the stakeholder relations section.

Call Details

The earnings call focused on the financial results and operations for the quarter ended June 30, 2026. Management responded to questions from analysts and investors regarding the company’s performance during this period.

Compliance and Disclosure

Sridhar S., Group Company Secretary and Legal & Compliance Officer, signed the submission to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). The filing serves as a record of the completed disclosure obligation for the quarter.

Investors can access the recording via the link provided in the company’s investor relations portal. The document confirms that all procedural requirements for post-earnings disclosure have been met for Q1FY27.

Narayana Hrudayalaya Limited reported a consolidated operating revenue of ₹26,836 million in Q1FY27, marking a 78.0% year-on-year increase driven primarily by the inclusion of its newly acquired United Kingdom business operations. Consolidated net profit (PAT) rose to ₹2,073 million from ₹1,961 million in the year-ago period. The Board of Directors approved these unaudited standalone and consolidated financial results on July 31, 2026, following a limited review by statutory auditors Deloitte Haskins & Sells LLP.

Segment Performance and Margin Dynamics

The revenue growth was significantly bolstered by the UK operations, which contributed substantially in their third quarter under Narayana Hrudayalaya's ownership. Excluding the UK, domestic India revenue grew robustly by 16.6% to ₹13,196 million, while Cayman Islands revenue also saw expansion. The standalone segment reported total income of ₹11,275.15 million, up from ₹9,595.77 million in Q1FY26, with standalone PAT rising to ₹1,378.55 million from ₹873.71 million.

Despite robust volume growth, profitability faced headwinds. Professional fees to doctors increased significantly, and employee benefit expenses jumped, impacting margins. Consequently, while consolidated EBITDA grew to ₹5,052 million from ₹3,607 million, the consolidated EBITDA margin contracted to 18.8% (as per investor presentation) or 17.50% (as per earlier disclosure), reflecting rising professional fees and employee benefits that outpaced top-line growth across the India and Cayman segments.

Operational Highlights and Integration

Dr. Emmanuel Rupert, Managing Director and Group CEO, highlighted strong patient footfall in India, supported by the expanding Integrated Care ecosystem including clinics and insurance. The Cayman business remained stable, aided by the One Health insurance platform. The UK business, now in its third quarter under Narayana Hrudayalaya, showed stable performance with separation from its erstwhile parent approaching completion.

Operationally, the Narayana Institute of Cardiac Sciences in Bangalore performed 2,137 cardiac surgeries in Q1FY27 and conducted 19 Pulse Field Ablation procedures for Atrial Fibrillation in June 2026. Narayana Hospital Gurugram operationalized the CUVIS Ortho Robotic System and Thulium Laser System, enabling advanced minimally invasive procedures.

Balance Sheet and Corporate Developments

As of June 30, 2026, consolidated total borrowings less cash and bank balance and investments stood at ₹19,671 million, resulting in a net debt-to-equity ratio of 0.42. This includes foreign currency debt components worth US $115 million and GBP £150 million. The standalone debt-to-equity ratio was 0.73. Net worth increased to ₹47,336 million (consolidated shareholder equity).

Structural reorganizations remain pending final approval from the National Company Law Tribunal (NCLT). The merger scheme for Meridian Medical Research & Hospital Ltd. awaits final orders after receiving approvals in January 2026. Similarly, the demerger scheme involving NH Integrated Care Private Limited is pending NCLT orders following April 2026 approvals. Neither scheme impacted Q1FY27 results. The company will host a conference call on August 3, 2026, to discuss these results.